{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:25:04Z","timestamp":1786116304105,"version":"build-2736575974"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"DOI":"10.1007\/s11239-026-03305-4","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T13:20:21Z","timestamp":1778678421000},"page":"1540-1548","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of anticoagulation management in patients with suspected heparin-induced thrombocytopenia awaiting diagnosis confirmation"],"prefix":"10.1007","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-6005-0738","authenticated-orcid":false,"given":"Alyssa R.","family":"George","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9208-2354","authenticated-orcid":false,"given":"Katelyn W.","family":"Sylvester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4942-6689","authenticated-orcid":false,"given":"Dareen M.","family":"Kanaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7885-4215","authenticated-orcid":false,"given":"Delaney M.","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2962-8048","authenticated-orcid":false,"given":"Kenneth E.","family":"Lupi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7997-649X","authenticated-orcid":false,"given":"Brian R.","family":"Schuler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6445-582X","authenticated-orcid":false,"given":"Jean M.","family":"Connors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"issue":"2","key":"3305_CR1","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1177\/1358863X19898253","volume":"25","author":"M Hogan","year":"2020","unstructured":"Hogan M, Berger JS (2020) Heparin-induced thrombocytopenia (HIT): review of incidence, diagnosis, and management. Vasc Med 25(2):160\u2013173. https:\/\/doi.org\/10.1177\/1358863X19898253","journal-title":"Vasc Med"},{"key":"3305_CR2","doi-asserted-by":"publisher","unstructured":"Carr\u00e9 J, Jourdi G, Gendron N, Helley D, Gaussem P, Darnige L (2021) Recent advances in anticoagulant treatment of immune thrombosis: a focus on direct oral anticoagulants in heparin-induced thrombocytopenia and anti-phospholipid syndrome. Int J Mol Sci 23(1). https:\/\/doi.org\/10.3390\/ijms23010093","DOI":"10.3390\/ijms23010093"},{"issue":"19","key":"3305_CR3","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1056\/NEJMc1510993","volume":"373","author":"A Greinacher","year":"2015","unstructured":"Greinacher A (2015) Heparin-induced thrombocytopenia. N Engl J Med 373(19):1883\u20131884. https:\/\/doi.org\/10.1056\/NEJMc1510993","journal-title":"N Engl J Med"},{"issue":"8","key":"3305_CR4","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1161\/CIRCULATIONAHA.106.632653","volume":"114","author":"SA Baroletti","year":"2006","unstructured":"Baroletti SA, Goldhaber SZ (2006) Heparin-induced thrombocytopenia. Circulation 114(8):355\u2013356. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.106.632653","journal-title":"Circulation"},{"issue":"1","key":"3305_CR5","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1161\/ATVBAHA.120.315445","volume":"41","author":"GM Arepally","year":"2021","unstructured":"Arepally GM, Padmanabhan A (2021) Heparin-induced thrombocytopenia: a focus on thrombosis. Arterioscler Thromb Vasc Biol 41(1):141\u2013152. https:\/\/doi.org\/10.1161\/ATVBAHA.120.315445","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"3305_CR6","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1182\/blood.V96.3.846","volume":"96","author":"A Greinacher","year":"2000","unstructured":"Greinacher A, Eichler P, Lubenow N, Kwansy H, Luz M (2000) Heparin-induced thrombocytopenia complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood 96(3):846\u2013851. https:\/\/doi.org\/10.1182\/blood.V96.3.846","journal-title":"Blood"},{"issue":"22","key":"3305_CR7","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1182\/bloodadvances.2018024489","volume":"2","author":"A Cuker","year":"2018","unstructured":"Cuker A, Arepally GM, Chong BH et al (2018) American society of hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv 2(22):3360\u20133392. https:\/\/doi.org\/10.1182\/bloodadvances.2018024489","journal-title":"Blood Adv"},{"key":"3305_CR8","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1007\/s11239-016-1408-6","volume":"42","author":"BM Ritchie","year":"2016","unstructured":"Ritchie BM, Sylvester KW, Reardon DP, Churchill WW, Berliner N, Connors JM (2016) Treatment of heparin-induced thrombocytopenia before and after the implementation of a hemostatic and antithrombotic stewardship program. J Thromb Thrombolysis 42:616\u2013622. https:\/\/doi.org\/10.1007\/s11239-016-1408-6","journal-title":"J Thromb Thrombolysis"},{"key":"3305_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2024.102423","author":"RL Zon","year":"2024","unstructured":"Zon RL, Sylvester KW, Rubins D, Grandoni J, Kelly J, Timilsina S, Akladious M, Patel R, Connors JM (2024) Electronic alerts to improve management of heparin-induced thrombocytopenia. Res Pract Thromb Haemost. https:\/\/doi.org\/10.1016\/j.rpth.2024.102423","journal-title":"Res Pract Thromb Haemost"},{"key":"3305_CR10","unstructured":"PF4 IgG [prescribing information]. Immuncor (2020) September Accessed July 21, 2025. https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf20\/K201570.pdf"},{"key":"3305_CR11","unstructured":"HemosIL Acustar [prescribing information], Werfen (2017) October Accessed July 21, 2025. https:\/\/www.accessdata.fda.gov\/cdrh_docs\/reviews\/K170854.pdf"},{"key":"3305_CR12","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.thromres.2022.02.018","volume":"213","author":"Y Xu","year":"2022","unstructured":"Xu Y, Gomes T, Wells PS, Peqeuno P, Johnson A, Sholzberg M (2022) Evaluation of definitions for oral anticoagulant-associated major bleeding: a population-based cohort study. Thromb Res 213:57\u201364. https:\/\/doi.org\/10.1016\/j.thromres.2022.02.018","journal-title":"Thromb Res"},{"issue":"01","key":"3305_CR13","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1160\/TH04-12-0825","volume":"94","author":"A Greinacher","year":"2005","unstructured":"Greinacher A, Farner B, Kroll H, Kohlmann T, Warkentin T, Eichler P (2005) Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. Thromb Haemost 94(01):132\u2013135. https:\/\/doi.org\/10.1160\/TH04-12-0825","journal-title":"Thromb Haemost"},{"issue":"1","key":"3305_CR14","doi-asserted-by":"publisher","first-page":"7225","DOI":"10.1182\/blood-2023-173542","volume":"142","author":"N Krishnan","year":"2023","unstructured":"Krishnan N, Boldig K, DeSuza KR, Miatech J, Quan WJR, Stack A (2023) When HIT testing hurts \u2013 the financial and clinical repercussions of heparin induced thrombocytopenia testing: a single center analysis. Blood 142(1):7225\u20137226. https:\/\/doi.org\/10.1182\/blood-2023-173542","journal-title":"Blood"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-026-03305-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-026-03305-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-026-03305-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T09:17:11Z","timestamp":1786007831000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-026-03305-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,13]]},"references-count":14,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["3305"],"URL":"https:\/\/doi.org\/10.1007\/s11239-026-03305-4","relation":{},"ISSN":["1573-742X"],"issn-type":[{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,13]]},"assertion":[{"value":"13 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.G., K.S., D.K., D.B., K.L., and B.S. have no disclosures concerning possible financial or personal relationships with commercial entities that may have a direct or indirect interest in the subject matter of this presentation. J.C. discloses consulting fees from Abbot Laboratories, Anthos Therapeutics, Bristol-Myers Squibb, Janssen Pharmaceuticals, Perosphere Technologies, Pfizer, Roche, and Sanofi S.A.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Ethics Committee of the Mass General Brigham Institutional Review Board waived the need for ethics approval and patient consent for the collection, analysis and publication of the retrospectively obtained and anonymized data for this non-interventional study.","order":2,"name":"Ethics","label":"<b>Ethical Considerations and Consent to Participate<\/b>","group":{"name":"EthicsHeading","label":"Declarations"}}]}}